Skip to Content

尊敬的客户：

目前国际形势复杂多变，关税政策尚不明朗，这可能对我们的产品价格产生一定影响。在此情况下，我们希望就订单事宜与您进行友好沟通。

基于当前的不确定性，如果您选择在此期间下单，我们将保留根据实际情况调整价格的权利。同时，我们也理解市场变化可能给您带来的困扰，因此如果在订单实际发货前因关税政策变动导致价格出现较大波动，默克将与您进行协商讨论并视情况对订单进行调整或取消。

关于应对近期政策变化的重要更新，请点击此处查看详情。

Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

T1063

Sigma-Aldrich

Thrombin from human plasma

lyophilized powder, ≥2800 NIH units/mg protein (E1%/280, 18.3)

Synonym(s):

Factor IIa

Sign Into View Organizational & Contract Pricing

Select a Size

250 μG
¥5,675.96

¥5,675.96

Estimated to ship on2025年5月12日Details

A recombinant, preservative-free antibody is available for your target. Try ZRB04338
Request a Bulk Order
All Photos(1)

Select a Size

Change View
250 μG
¥5,675.96

About This Item

CAS Number:
9002-04-4
Enzyme Commission number:
3.4.21.5 (BRENDA, IUBMB)
EC Number:
232-648-7
MDL number:
MFCD00082072
UNSPSC Code:
12352204
NACRES:
NA.54

¥5,675.96

Estimated to ship on2025年5月12日Details

A recombinant, preservative-free antibody is available for your target. Try ZRB04338
Request a Bulk Order

form

lyophilized powder

Quality Level

200

specific activity

≥2800 NIH units/mg protein (E1%/280, 18.3)

mol wt

37.4 kDa

impurities

HIV, hepatitis B and hepatitis C, tested negative

UniProt accession no.

P00734

application(s)

diagnostic assay manufacturing

storage temp.

−20°C

Gene Information

human ... F2(2147)

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
T7009T6634T6884
Thrombin 来源于人类血浆 lyophilized powder, ≥2800 NIH units/mg protein (E1%/280, 18.3)

T1063

Thrombin 来源于人类血浆

Thrombin 来源于人类血浆 lyophilized powder, ≥1,000 NIH units/mg protein (E1%/280, 18.3)

T7009

Thrombin 来源于人类血浆

凝血酶 来源于牛血浆 lyophilized powder, 600-2,000 NIH units/mg protein (biuret)

T6634

凝血酶 来源于牛血浆

Thrombin 来源于人类血浆 lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280, 18.3)

T6884

Thrombin 来源于人类血浆

specific activity

≥2800 NIH units/mg protein (E1%/280, 18.3)

specific activity

≥1,000 NIH units/mg protein (E1%/280, 18.3)

specific activity

600-2,000 NIH units/mg protein (biuret)

specific activity

≥2,000 NIH units/mg protein (E1%/280, 18.3)

form

lyophilized powder

form

lyophilized powder

form

lyophilized powder

form

lyophilized powder

application(s)

diagnostic assay manufacturing

application(s)

diagnostic assay manufacturing

application(s)

diagnostic assay manufacturing

application(s)

-

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

mol wt

37.4 kDa

mol wt

37.4 kDa

mol wt

heavy chain ~33 kDa, light chain ~5 kDa

mol wt

37.4 kDa

General description

Thrombin is the final coagulation protease in regard to hemostasis, promoting both procoagulant and anticoagulant effects.

Application

Thrombin is used for site specific cleavage of recombinant fusion proteins containing an accessible thrombin recognition site for removal of affinity tags. Thrombin has been used in a study to evaluate the in vitro effect of low molecular weight heparin on thrombin generation in cirrhotic patients at different stages of liver disease. [1]

Biochem/physiol Actions

Serine protease that selectively cleaves Arg-Gly bonds in fibrinogen to form fibrin and fibrinopeptides A and B.

Unit Definition

Activity is expressed in NIH units obtained by direct comparison to a NIH Thrombin Reference Standard

Physical form

Lyophilized from 0.02 M Bis/Tris buffer, pH 6.5, 0.15 M NaCl and 0.1% PEG-8000

Analysis Note

The NIH assay procedure uses 0.2 ml diluted plasma (1:1 with saline) as a substrate and 0.1ml of thrombin sample (stabilized in a 1% buffered albumin solution) based on a modification of the method of Biggs. Only clotting times in the range of 15-25 seconds are used for determining thrombin concentrations.

Other Notes

View more information on thrombin at www.sigma-aldrich.com/enzymeexplorer.

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

inhibitor

Product No.
Description
Pricing

substrate

Product No.
Description
Pricing

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H315,H319,H334,H335

Hazard Classifications

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

高风险级别生物产品--人源产品

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number
    0000349240
    0000334891
    0000311033
    0000334891
    0000311033

    Don't see the Right Version?

    If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

    Search for a COA

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Giselle Barbosa-Lima et al.
    Journal of leukocyte biology, 108(4), 1293-1306 (2020-07-15)
    Dengue is characterized as one of the most important arthropod-borne human viral diseases, representing a public health problem. Increased activation of immune cells is involved in the progression of infection to severe forms. Recently, our group demonstrated the contribution of
    Zhong Feng Gao et al.
    Nature protocols, 15(2), 316-337 (2020-01-10)
    Current visual biosensing methods, including colorimetric-based, fluorescence-based and chemiluminescence-based methods, are inappropriate for the hundreds of millions of people affected by color blindness and color weakness. Compared with these available methods, a droplet motion-based strategy might be a promising protocol
    Otilia Obreja et al.
    Experimental dermatology, 15(1), 58-65 (2005-12-21)
    Activation of protease-activated receptors (PAR) can induce vasodilation (VD) and increase of vascular permeability either directly by stimulating endothelial cells or indirectly via activation of nociceptors and subsequent release of neuropeptides (neurogenic inflammation). We aimed to estimate the relative contribution
    Sooyeon Kim et al.
    RSC advances, 8(37), 20822-20828 (2018-06-06)
    We propose a new sensor design that maximizes fluorescence contrast, inspired by whispering-gallery mode lasing (WGM). Aptamer-modified glass microspheres (cf. 1-38 μm) and thrombin are used as a model sensory cavity and target protein, respectively. Two types of microsphere are
    D David et al.
    British journal of haematology, 113(3), 604-615 (2001-05-31)
    In haemophilia A, the functional defect at the molecular level of most factor VIII (FVIII) missense mutations remains unknown. Site-directed mutagenesis of B domain-deleted FVIII cDNA (FVIIISQ) was used to introduce two mutations associated with severe cross-reacting material (CRM)-negative (FVIII-C329S)
    View All Related Papers

    Articles

    Thrombin Factor IIa

    Thrombin Factor IIa is an endolytic serine protease that selectively cleaves the Arg--Gly bonds of fibrinogen to form fibrin and release fibrinopeptides A and B.

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service